|
Published by: Visiongain
Published: Aug. 7, 2009 - 122 Pages
Table of Contents
- 1 Executive Summary
- 2 AMD and Diabetic Retinopathy
- 2.1 The Eye
- 2.1.1 The Human Eye
- 2.1.2 The Retina and Vision
- 2.2 Age-Related Macular Degeneration (AMD)
- 2.2.1 Early Stages of AMD
- 2.2.2 Advanced Dry AMD (Geographic Atrophy)
- 2.2.3 Wet AMD
- 2.2.4 AMD Causes and Risk Factors
- 2.3 Diabetic Retinopathy (DR)
- 2.3.1 Causes and Types of Diabetic Retinopathy
- 2.3.2 Non-Proliferative Diabetic Retinopathy
- 2.3.3 Diabetic Macular Edema
- 2.3.4 Proliferative Diabetic Retinopathy (PDR)
- 2.3.5 Risk Factors and Prevalence of Diabetic Retinopathy
- 2.4 Diagnosis and Prevalence of AMD and DR
- 2.4.1 Diagnosis
- 2.4.2 Prevalence
- 2.5 Other Retinal Disorders
- 3 Treatments for AMD and Diabetic Retinopathy
- 3.1 Treatment of Wet AMD
- 3.1.1 Visudyne
- 3.1.2 Macugen
- 3.1.3 Retaane
- 3.1.4 Lucentis
- 3.1.5 Avastin
- 3.2 Treatment of Dry AMD
- 3.3 Treatments for Diabetic Retinopathy
- 3.3.1 Laser and Surgical Treatments are the Main Treatments for Diabetic Retinopathy
- 3.3.2 Triamcinolone Acetonide
- 3.3.3 Lisinopril
- 3.3.4 VEGF Inhibitors
- 3.3.5 Dobesilate
- 4 The World AMD and Diabetic Retinopathy Market, 2009-2024
- 4.1 The Retinal Disorder Market
- 4.1.1 The Retinal Disorder Market in 2008
- 4.1.2 Retinal Disorders Market Forecast, 2009-2014
- 4.1.3 Retinal Disorders Market Forecast, 2014-2024
- 4.2 The World AMD Market, 2008
- 4.2.1 Leading AMD Drugs in 2008
- 4.2.2 Leading AMD Drug Manufacturers
- 4.3 AMD Market Forecast
- 4.3.1 New Treatments for Geographic Atrophy: AMD Market Forecast, 2009-2014
- 4.3.2 AMD Market Forecast, 2014-2024
- 4.4 Diabetic Retinopathy Market
- 4.4.1 The Diabetic Retinopathy Market in 2008
- 4.4.2 An Alternative to Surgery: Diabetic Retinopathy Market Forecast, 2009-2014
- 4.4.3 Diabetic Retinopathy Market Forecast, 2014-2024
- 4.5 Lucentis Sales Forecasts
- 4.5.1 The Future of Lucentis Hinges on Off-Label Avastin Use
- 4.5.2 Lucentis Sales Forecast, 2009-2014
- 4.5.3 Lucentis Sales Forecast, 2014-2024
- 4.5.4 Alternative Lucentis Sales Forecast, 2009-2024
- 4.6 Visudyne Sales Forecast, 2009-2014
- 5 The AMD and Diabetic Retinopathy Pipelines
- 5.1 The Wet AMD Pipeline
- 5.1.1 Monoclonal Antibodies and Corticosteroid Implants
- 5.1.2 siRNA Molecules
- 5.1.3 Stem Cells and Other Therapies
- 5.2 The Dry AMD Pipeline
- 5.3 The Diabetic Retinopathy Pipeline
- 5.3.1 Corticosteroid Implants
- 5.3.2 Anti-VEGF Treatments
- 5.3.3 Early-Stage Diabetic Retinopathy Pipeline
- 5.4 The Pipeline for Other Retinal Disorders
- 5.5 AMD and DR Pipeline Drugs in Detail
- 5.5.1 VEGF Trap-Eye/Aflibercept (Regeneron/Bayer)
- 5.5.2 Posurdex/SK-0503 (Allergan/Sanwa Kagaku Kenkyusho)
- 5.5.3 Bevasiranib (Opko)
- 5.5.4 Avastin and Lucentis Comparison Trials (CATT)
- 5.5.5 PF-4523655 (Quark/Pfizer)
- 5.5.6 Visudyne and Lucentis (QLT/Novartis)
- 5.5.7 Pazopanib (GSK)
- 5.5.8 TG100801 (TargeGen)
- 5.5.9 Zybrestat (Oxigene/Symphony ViDA)
- 5.5.10 ATG-3 (CoMentis)
- 5.5.11 Sirolimus (MacuSight/Santen)
- 5.5.12 Iluvien (Alimera/pSivida)
- 5.5.13 NT-501 (Neurotech)
- 5.5.14 OT-551 (Othera)
- 5.5.15 Sustained-Release Brimonidine (Allergan)
- 5.5.16 Fenretinide (Sirion Therapeutics)
- 5.5.17 NT-503 (Neurotech)
- 5.5.18 Stem Cells (University College of London/Pfizer)
- 5.5.19 Opko’s siRNA Drug Candidates
- 5.5.20 Arxxant (Eli Lilly/Alcon/Takeda)
- 5.5.21 Lucentis (Roche/Novartis)
- 5.5.22 Macugen (Pfizer)
- 5.5.23 Vitreosolve (Vitreoretinal Technologies)
- 5.5.24 Atacand/TCV-116 (AstraZeneca)
- 5.5.25 Microplasmin (ThromboGenics)
- 5.5.26 RPE65 Gene Therapy (Targeted Genetics)
- 5.5.27 QLT091001 (QLT/Retinagenix)
- 6 Issues Affecting the AMD and Diabetic Retinopathy Pharmaceutical Markets
- 6.1 SWOT Analysis of the AMD and Diabetic Retinopathy Pharmaceutical Markets
- 6.2 Intense Research and Development Activity
- 6.2.1 New Drug Formulations
- 6.2.2 Sustained-Release Ocular Implants
- 6.2.3 Novel Biologic Drugs
- 6.2.4 New Ophthalmic Therapeutic Applications for Drugs
- 6.3 Off-Label Avastin Use for Retinal Disorders
- 6.3.1 Avastin and Lucentis
- 6.3.2 Off-Label Retinal Applications of Avastin
- 6.3.3 History of Avastin Use for Wet AMD
- 6.3.4 The CATT Study
- 6.3.5 The Future for Off-Label Avastin
- 6.4 ‘Greying’ of the World Population
- 6.5 Prevalence of Retinal Diseases
- 6.5.1 Prevalence of AMD, 2008
- 6.5.2 Forecast AMD Prevalence, 2024
- 6.5.3 Prevalence of Diabetes, Proliferative Diabetic Retinopathy and Diabetic Macular Edema, 2008
- 6.5.4 Forecast Prevalence of Diabetes, Proliferative Diabetic Retinopathy and Diabetic Macular Edema, 2024
- 6.6 Reimbursement for AMD and Diabetic Retinopathy Pharmaceuticals
- 6.6.1 Pressure on Healthcare in Current Difficult Economic Environment
- 6.6.2 Prospects for Reimbursement for AMD and DR Drugs
- 6.7 Diagnosis and Screening for Retinal Disorders
- 6.8 Laser and Surgical Treatments for Diabetic Retinopathy Will Compete with New Drugs
- 6.8.1 Current Laser Treatments
- 6.8.2 Will Drugs Replace Laser Therapy?
- 7 AMD and Diabetic Retinopathy Regional Markets
- 7.1 Retinal Disorder Country Markets, 2008
- 7.2 Retinal Disorder Regional Forecast, 2009-2024
- 7.2.1 The US Retinal Disorder Market, 2009-2024
- 7.2.2 The European Retinal Disorder Market, 2009-2024
- 7.2.3 The Retinal Disorder Market in the Rest of the World, 2009-2024
- 8 Opinion from Industry Experts
- 8.1 Edward Danse, President and CEO of Neurotech
- 8.1.1 Retinal Disorders with Greatest Unmet Patient Need
- 8.1.2 Neurotech’s AMD Pipeline
- 8.1.3 Progress of NT-501 Clinical Trials in Geographic Atrophy Patients
- 8.1.4 Screening Programmes for AMD
- 8.1.5 Potential Lifetime of NT-501 in the Eye
- 8.1.6 Other Potential Treatments for Geographic Atrophy
- 8.1.7 Potential Use of NT-501 in Diabetic Retinopathy
- 8.2 Ken Green, Ph.D., Chief Scientific Officer and Dave Holland, Founder/VP Marketing, Alimera Sciences
- 8.2.1 Main Unmet Clinical Needs Among Diabetic Retinopathy Patients
- 8.2.2 Development of Iluvien for Diabetic Macular Edema
- 8.2.3 Update on Progress of Iluvien’s Phase III Trials
- 8.2.4 Reimbursement Prospects for Corticosteroid Inserts
- 8.2.5 Future for Laser Therapy in Diabetic Retinopathy
- 8.2.6 Possible Future Treatment for Dry AMD and Geographic Atrophy
- 8.2.7 Clinical Trials for Iluvien for Wet AMD and RVO
- 8.3 Al Reaves, Ph.D., Senior Vice President of Clinical Development, Othera Pharmaceuticals
- 8.3.1 Othera's Geographic Atrophy Drug: OT-551
- 8.3.2 New Drugs for Retinal Disorders Currently with No Treatments
- 9 Conclusions
- 9.1 AMD and Diabetic Retinopathy
- 9.2 Increasing Prevalence of AMD and Diabetic Retinopathy
- 9.3 Current Treatments for AMD and Diabetic Retinopathy
- 9.4 The Retinal Disorder Market in 2008
- 9.5 Retinal Disorders Market Forecast, 2009-2024
- 9.6 Lucentis Market Forecast, 2009-2024
- 9.7 The AMD and Diabetic Retinopathy Pipelines
- 9.8 The AMD Pipeline
- 9.9 The Diabetic Retinopathy Pipeline
- List of Tables
- Table 2.1 Wet AMD Types
- Table 2.2 AMD and DR Diagnosis Methods
- Table 2.3 Prevalence of AMD and DR, 2008
- Table 2.4 Other Retinal Disorders
- Table 3.1 Currently-Marketed AMD Treatments
- Table 3.2 Lucentis Regulatory Approval and Launch Dates
- Table 4.1 Retinal Disorder Market in 2008
- Table 4.2 World Retinal Disorders Market Forecast, 2009-2014
- Table 4.3 World Retinal Disorders Market Forecast, 2015-2024
- Table 4.4 AMD Market, 2008: Leading Drugs
- Table 4.5 AMD Market, 2008: Leading Manufacturers
- Table 4.6 Drivers and Restraints for the AMD Market, 2009-2014
- Table 4.7 Drivers and Restraints for the DR Market, 2009-2014
- Table 4.8 Drivers and Restraints for Lucentis Revenues, 2009-2014
- Table 4.9 Lucentis Market Forecast (Main Forecast), 2009-2014
- Table 4.10 Lucentis Market Forecast (Main Forecast), 2015-2024
- Table 4.11 Lucentis Market Forecast (Alternative Forecast), 2009-2014
- Table 4.12 Lucentis Market Forecast (Alternative Forecast), 2015-2024
- Table 4.13 Visudyne Market Forecast, 2009-2014
- Table 5.1 Key Late-Stage AMD Pipeline Drugs
- Table 5.2 Selected Early-Stage AMD Pipeline Drugs
- Table 5.3 Key Late-Stage Diabetic Retinopathy Pipeline Drugs
- Table 5.4 Selected Early-Stage DR Pipeline Drugs
- Table 5.5 Other Retinal Disorder Pipeline Drugs
- Table 5.6 Lucentis Clinical Trials in Progress
- Table 6.1 SWOT Chart for the AMD and DR Pharmaceutical Markets, 2009
- Table 6.2 World Population Forecast, 2008-2024
- Table 6.3 Population Forecasts in AMD and DR Markets, 2008 & 2024
- Table 6.4 Global, US and European AMD Prevalence, 2008
- Table 6.5 Forecast Global, US and European AMD Prevalence, 2024
- Table 6.6 Global, US and European DME, PDR and Diabetes Prevalence, 2008
- Table 6.7 Forecasted Global, US and European DME, PDR and Diabetes Prevalence, 2024
- Table 7.1 Leading Retinal Disorder Pharmaceutical Markets, 2008
- Table 7.2 Regional Retinal Disorders Market Forecast, 2009-2014
- Table 7.3 Regional Retinal Disorders Market Forecast, 2015-2024
- Table 9.1 Global Prevalence of AMD and DR Complications, 2008 and 2024
- List of Figures
- Figure 4.1 Retinal Disorder Market in 2008
- Figure 4.2 World Retinal Disorder Market Forecast, 2009-2024
- Figure 4.3 Revenue Forecast by Retinal Disorder Type, 2009-2024
- Figure 4.4 Market Share Forecast by Retinal Disorder Type, 2009-2024
- Figure 4.5 AMD Market, 2008: Leading Drugs
- Figure 4.6 AMD Market, 2008: Leading Manufacturers
- Figure 4.7 Global AMD Market Forecast, 2009-2024
- Figure 4.8 Global DR Market Forecast, 2009-2024
- Figure 4.9 Lucentis Market Forecast (Main Forecast), 2009-2024
- Figure 4.10 Lucentis Market Forecast (Alternative Forecast), 2009-2024
- Figure 4.11 Visudyne Market Forecast, 2009-2014
- Figure 6.1 Forecasted World Population Aged 65 or Over, 2008-2024
- Figure 6.2 Population Forecasts in Leading AMD and DR Markets, 2008 & 2024
- Figure 6.3 Global, US and European AMD Prevalence, 2008
- Figure 6.4 Global, US and European AMD Prevalence, 2008 and 2024
- Figure 6.5 Global, US and European DME and PDR Prevalence, 2008
- Figure 6.6 Global, US and European Diabetes Prevalence, 2008 and 2024
- Figure 6.7 Global, US and European New Cases of DME, 2008 and 2024
- Figure 6.8 Global, US and European New Cases of PDR, 2008 and 2024
- Figure 7.1 Leading Retinal Disorder Pharmaceutical Markets, 2008
- Figure 7.2 Regional Retinal Disorders Market Forecast, 2009-2014
- Figure 7.3 Market Share Forecast by Regional Retinal Disorder Market, 2009-2024
- Figure 9.1 World Retinal Disorder Market Forecast, 2009-2024
- Figure 9.2 Lucentis Market Forecast, 2009-2024
- Companies Listed
- Alcon (Nestlé)
- Alimera Sciences
- Allergan
- American Academy of Ophthalmology (AAO)
- American Society of Retinal Specialists (ASRS)
- AstraZeneca
- Bausch & Lomb
- Bayer
- BioDiem
- Bristol-Myers Squibb
- Centre for Molecular and Vascular Biology, KU Leuven
- Chugai
- CoMentis
- Diabetic Retinopathy Clinical Research Network (DRCR)
- Eli Lilly
- Emory University
- ESBATech
- Esteve
- European Medicines Agency (EMEA)
- Eyetech
- Food and Drug Administration (FDA)
- Fovea
- Gene Signal
- Genentech
- GenVec
- Gilead
- GlaxoSmithKline (GSK)
- iCo
- Isis
- Jerini Ophthalmic
- KAI Pharmaceuticals
- Lpath
- Ludwig-Maximilians-Universität
- MacuSight
- Merck & Co.
- Moorfields Eye Hospital
- National Eye Institute (NEI)
- National Health Service (NHS)
- National Institute for Health and Clinical Excellence (NICE)
- National Institute for Health Research (NIHR)
- National Institutes of Health (NIH)
- Neurotech
- NeXstar
- Novartis
- OM Pharmaceuticals
- Ophthotech
- Opko
- OSI Pharmaceuticals
- Othera
- Oxford BioMedica
- Oxigene
- Pfizer
- Potentia
- pSivida
- QLT
- Quark
- Regeneron
- Retinagenix
- Roche
- Santen
- Sanwa Kagaku Kenkyusho
- Shire
- Sirion Therapeutics
- Sirna Therapeutics
- Sirnaomics
- Suzuken
- Symphony ViDA
- Takeda
- TargeGen
- Targeted Genetics
- ThromboGenics
- University College London
- University of Florida
- University of Kentucky College of Medicine
- Vitreoretinal Technologies
- Wyeth
AbstractThe global prevalences of AMD (age-related macular degeneration) and diabetic retinopathy are increasing due to rising numbers of older people worldwide. In addition, the world is facing a "diabetes epidemic", with rapidly-increasing numbers of people with diabetes and diabetic retinopathy. A clear market opportunity exists for pharmacological treatments for diabetic retinopathy, dry AMD and other retinal disorders. From 2009 to 2024, such treatments could repeat the commercial success that Lucentis achieved in the treatment of wet AMD. Our latest pharma report - World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 - examines prospects for the retinal disorder market over the next 15 years.
The rapid commercial success of Lucentis in treating wet AMD illustrates the high rewards for successful novel treatments in the retinal disorders market. There is a clear market opportunity for other drugs to treat diabetic retinopathy, a condition for which there are currently no approved pharmacological treatments. Our analysts believe there are further commercial opportunities for new treatments for geographic atrophy (advanced dry AMD) and for wet AMD. There is a need for clear advantages over existing wet AMD therapies, for improved clinical outcomes and ease of dosing. This report analyses prospects there.
Comprehensive analysis of the market area
World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 55 tables and figures and three full interviews with experts in the sector. The result is a comprehensive market- and industry-centred report, with detailed analyses and informed opinion to benefit your work.
Why you should buy World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024
You will receive the following benefits when you order our report:
- You will receive sales forecasts for the global retinal disorder market, AMD market,diabetic retinopathy market and the market for other retinal disorders, together with sales forecasts for leading brands, from 2009 to 2024
- You will read expert opinion from key-opinion leaders in the retinal disorders pharmaceutical sector, including full transcripts of interviews not published elsewhere
- You will gain a comprehensive assessment of strengths, weakness, opportunities and threats for this sector, including discussion of market drivers and restraints
- You will receive an examination of the future prospects for Lucentis in the face of competition from off-label use of Avastin, with supporting market forecasts
- You will obtain a regional analysis of the AMD and diabetic retinopathy markets, with sales forecasts
- You will receive in-depth analyses of the pharmaceutical pipelines for AMD, diabetic retinopathy and other retinal disorders.
You can obtain this report today
World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 will provide you with the information that you need to understand this dynamic and rapidly-expanding sector. Which pipeline drug candidates are the ones to watch? When are they likely to reach the market? In which geographical regions are AMD and diabetic retinopathy complications forecasted to increase most in prevalence? This new report answers those questions and much more besides. Do you want to know more about this important market? You can stay ahead by ordering this report today
Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
